Wednesday, May 18, 2016 10:06:27 AM
«ACTUAL ASPECTS OF EXTRACORPOREAL BLOOD PURIFICATION IN INTENSIVE CARE»
Moscow
June 3 – 4, 2016
Dear Colleagues, Participants and Guests of the Conference!
The years insensibly passed since the first Russian Conference dedicated to the problems of extracorporeal hemocorrection in patients of the intensive care units was held in 1988. And now we have been already meeting for the tenth time in the hospitable “Heart House” on Rublevskoe highway in June 2016. Of course, analyzing the results of the previous forums, it should be said about the importance of these meetings for the development of intensive care in our country. Just have a look what a wide variety of methods of extracorporeal treatment has become available for the experts who work with the population of critically ill patients. It notes that more and more clinics almost routinely use different methods of extracorporeal blood correction. Today it is difficult to imagine a modern intensive care unit which is not performing the extracorporeal procedures. Undoubtedly, this contributed to our regular meetings over the past 18 years, where the leading experts from Russia and abroad shared their successes and achievements with us and determined the direction of further studies. Year by year there has been progress in the level of reports provided by local authors starting from uninteresting messages within the framework of the first conference and finishing by the argumentative and thoughtful answers within the next forums. Thus, assessing the results of the last 10 conferences, one can certainly say that they have been of great benefit to the development of clinical medicine in the country. The main objectives of our following meetings should be the evaluation of the effectiveness of new methods of extracorporeal blood correction and their introduction into clinical practice, organization and conduction of fundamental and large multicenter randomized trials.
The scientific program of the conference traditionally includes problems of diagnostics and extracorporeal treatment of acute kidney injury and acute liver failure in children and adults. One of the sections will be fully devoted to the questions of diagnosis and intensive therapy of kidney injury in patients after cardiac surgery as one of the most common causes of renal dysfunction. The possibility of using extracorporeal techniques in the treatment of sepsis will also be fully discussed. The reports will present the results of various sorption cartridges, made both by domestic and foreign manufacturers, and much more other things.
As previously, the leading researchers from Europe, Japan and the USA will take part in the conference. We will be extremely pleased to welcome Professor Ravindra Mehta, a well-known nephrologist from the USA who took an active part in the first our conference 18 years ago. Another famous nephrologist from the UK is Marlies Ostermann who will give lectures on the effectiveness of the use of high doses of loop diuretics in patients in the intensive care unit and the possibilities of extracorporeal blood correction in the treatment of acute pancreatitis. One of the founders of the current concepts of the pathophysiology and pathogenesis of sepsis, Professor Steven Opal from the United States will reveal the principles of the modern classification of sepsis and provide new data on the clinical application of extracorporeal sorption methods in the intensive care of this severe pathology. French scientist, Thomas Rimmele, will present data on sepsis-induced immunosuppression in the patients in the ICU, and Professor Zsolt Molnar from Hungary will talk about his clinical experience in using «CytoSorb» columns for the purpose of cytokine elimination in septic shock. Interesting topics are stated in the framework of the satellite symposia, organized by general partners of the conference and world leaders in the production of equipment and accessories for efferent treatments – “Fresenius Medical Care” and ZAO "Fresenius SP" (Germany - Russia), as well as "B/B Medical" and “Toray” (Russia - Japan).
The Organizing Committee of IX Conference "Actual aspects of extracorporeal blood purification in intensive care" invites all specialists of our country to take an active part in the regular forum. We sincerely hope that presented reports and lectures will allow the delegates and guests of the conference to evaluate and interpret the results of their own daily work, introduce new methods of diagnosis and treatment and increase work efficiency of professionals from the ICU.
https://racvs.ru/en/events/x_yubileynaya_mezhdunarodnaya_konferentsiya_aktualnye_aspekty_ekstrakorporalnogo_ochishcheniya_krovi/
Recent CTSO News
- Form 8-K - Current report • Edgar (US Regulatory) • 05/06/2024 09:00:30 PM
- CytoSorbents May 6, 2024 Virtual KOL and Analyst-Investor Day: STAR-T Pivotal Trial Topline Results & Real World Experience with Antithrombotic Drug Removal in Europe • GlobeNewswire Inc. • 05/02/2024 11:00:00 AM
- CytoSorbents to Report First Quarter 2024 Operating and Financial Results • GlobeNewswire Inc. • 04/26/2024 11:00:00 AM
- STAR-T Pivotal Trial Results to Be Featured as a Late-Breaking Presentation at the 2024 American Association for Thoracic Surgery Annual Meeting • GlobeNewswire Inc. • 04/17/2024 11:00:00 AM
- CytoSorbents to Report Fiscal 2023 Operating and Financial Results • GlobeNewswire Inc. • 03/06/2024 12:00:00 PM
- CytoSorbents to Present at the TD Cowen 44th Annual Health Care Conference • GlobeNewswire Inc. • 02/08/2024 12:00:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/17/2024 10:20:45 PM
- Groundbreaking Randomized Controlled Trial Reports Excellent Clinical Outcomes Using CytoSorb® Intraoperatively in Heart Transplant Patients • GlobeNewswire Inc. • 01/17/2024 12:15:00 PM
- Form SC 13G - Statement of acquisition of beneficial ownership by individuals • Edgar (US Regulatory) • 01/08/2024 08:00:03 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 12/28/2023 09:49:02 PM
- CytoSorbents Provides Update on the STAR-T Trial and Reports Final Independent Data and Safety Monitoring Board Recommendation • GlobeNewswire Inc. • 12/28/2023 12:00:00 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 12/15/2023 09:35:14 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 12/15/2023 09:34:16 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 12/15/2023 09:34:14 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 12/15/2023 09:33:21 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 12/15/2023 09:32:55 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 12/15/2023 09:32:14 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 12/15/2023 09:31:42 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 12/15/2023 09:30:43 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 12/13/2023 02:15:22 PM
- CytoSorbents Announces Closing of $10.3 Million Registered Direct Offering • GlobeNewswire Inc. • 12/13/2023 02:15:00 PM
- Form 424B5 - Prospectus [Rule 424(b)(5)] • Edgar (US Regulatory) • 12/11/2023 09:10:44 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 12/11/2023 09:10:18 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 11/09/2023 09:20:25 PM
- CytoSorbents Reports Third Quarter 2023 Financial and Operational Results • GlobeNewswire Inc. • 11/09/2023 09:15:00 PM
NanoViricides Reports that the Phase I NV-387 Clinical Trial is Completed Successfully and Data Lock is Expected Soon • NNVC • May 2, 2024 10:07 AM
ILUS Files Form 10-K and Provides Shareholder Update • ILUS • May 2, 2024 8:52 AM
Avant Technologies Names New CEO Following Acquisition of Healthcare Technology and Data Integration Firm • AVAI • May 2, 2024 8:00 AM
Bantec Engaged in a Letter of Intent to Acquire a Small New Jersey Based Manufacturing Company • BANT • May 1, 2024 10:00 AM
Cannabix Technologies to Deliver Breath Logix Alcohol Screening Device to Australia • BLO • Apr 30, 2024 8:53 AM
Hydromer, Inc. Reports Preliminary Unaudited Financial Results for First Quarter 2024 • HYDI • Apr 29, 2024 9:10 AM